This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
TMDX Wins Full FDA IDE Approval for Next-Gen OCS ENHANCE Heart Trial
by Zacks Equity Research
TransMedics secures full FDA IDE approval for its OCS ENHANCE Heart trial, clearing a key hurdle and advancing its push to expand heart transplant use.
ISRGPositive Net Change ATRCPositive Net Change TMDXPositive Net Change GEHCPositive Net Change
medical medical-devices
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down
by Zacks Equity Research
BRKR's Q4 EPS miss estimates as margins plunge and shares fall 2.7% despite a revenue beat, while the 2026 outlook targets 4%-5% sales growth.
ISRGPositive Net Change ALGNPositive Net Change CAHPositive Net Change BRKRNegative Net Change
earnings medical medical-devices
ServisFirst Bancshares (SFBS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SFBSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How to Play Hologic Stock Post Q1 Earnings and Progress on Buyout?
by Moumi Mondal
HOLX's $18.3B Blackstone-TPG buyout nears close after Q1 miss. With shares near a $76 cash offer, the upside for HOLX investors looks dim.
MDTNegative Net Change HOLXPositive Net Change GEHCPositive Net Change
medical medical-devices
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
by Zacks Equity Research
NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.
NEONegative Net Change ATRCPositive Net Change ADMANegative Net Change VCYTNegative Net Change
medical medical-devices
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
by Zacks Equity Research
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
ANGOPositive Net Change ISRGPositive Net Change MASINegative Net Change DXCMPositive Net Change
earnings medical medical-devices
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
by Zacks Equity Research
PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.
DVAPositive Net Change CAHPositive Net Change PACBNegative Net Change DOCSPositive Net Change
earnings medical medical-devices
Arrow Electronics (ARW) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ARWPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Will ISRG's R&D Focus Following Solid Earnings Growth Drive Demand?
by Indrajit Bandyopadhyay
Intuitive Surgical balances 22% EPS growth with heavier 2026 R&D and expansion spending, betting near-term margin pressure will fuel long-term demand.
BSXNegative Net Change ISRGPositive Net Change MCKPositive Net Change
medical medical-devices
Is the Options Market Predicting a Spike in IQVIA Stock?
by Nandini Tamret
Investors need to pay close attention to IQVIA stock based on the movements in the options market lately.
IQVNegative Net Change
medical medical-devices